

Practitioner's Docket No. MWH-0002US2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chew, Anne; Denton R. Rex; Duda, Amy; Nandabalan, Krishnan; Stephens, Joel
Claiborne; and Windemuth, Adreas K.

Application No.: 10/010,802
Filed: November 9, 2001

Group No.: 1634
Examiner: Juliet Einsmann Switzer

For: DRUG TARGET ISOGENES: POLYMORPHISMS IN THE INTERLEUKIN 4 RECEPTOR
ALPHA GENE

Commissioner for Patents
Washington, D.C. 20231

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following papers are being facsimile transmitted to the Patent and
Trademark Office at (703) 872-9306 on the date shown below:

1. Second Preliminary Amendment to Claims and Response to Restriction Requirement (7 pages)
2. Petition and Fee for Extension of Time (37 C.F.R. § 1.136(a)) (2 pages)

FAX RECEIVED

OFFICIAL


APR 24 2003

GROUP 1600

Date:

April 23, 2003

Reg. No.: 47,934
Tel No.: 203-786-3468
Customer No.: 25106
s.shaner@genaisance.com



Signature of Practitioner
Sandra L. Shaner
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

Fractioner's Docket No. MWH-0002US2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chew et al.

Application No.: 10/010,802

Filed: November 9, 2001

Group No.: 1634

Examiner: Juliet Einsmann Switzer

For: DRUG TARGET ISOGENES: POLYMORPHISMS IN THE INTERLEUKIN 4 RECEPTOR
ALPHA GENE

Assistant Commissioner for Patents
Washington, D.C. 20231

**SECOND PRELIMINARY AMENDMENT TO CLAIMS AND RESPONSE TO
RESTRICTION REQUIREMENT**

(37 CFR §1.115 and MPEP 714.01(e); 37 CFR §1.143)

This preliminary amendment is submitted in response to the Office Action dated February 26, 2003, which required restriction between the claims. This paper is filed pursuant to MPEP 714.01(e) and is in compliance with 37 CFR §1.115. A one month extension of time has been requested in the attached petition, which authorizes the payment of the appropriate fees.